Look back at pharma news in the week to August 13, 2021

tpl-week-in-review-700x466

By Barbara Obstoj-Cardwell

Among last week’s notable news, US biotech firm bluebird bio revealed a double whammy on Wednesday, when it announced a US Food and Drug Administration clinical hold on its gene therapy Skysona (eli-cel) as well as its decision to pull out of Europe because of difficulties in gaining reimbursement for its products. AstraZeneca and partner FibroGen suffered a setback with the FDA issuing a complete response letter (CRL) on their anemia of chronic kidney disease candidate roxadustat. On the deal-making front, US biotech Seagen last week announced a licensing agreement with China’s RemeGen to develop disitamab vedotin as a treatment for various cancers, worth up to $2.2 billion. mRNA specialist Moderna released new data showing its COVID-19 vaccine Spikevax generated neutralizing antibodies against variants.

bluebird bio downgrade to market perform following business update

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology